The Conversation (0)
- NORTH AMERICA EDITIONAustraliaNorth AmericaWorld
Chart
Detailed Quote
Botanix Pharmaceuticals Ltd is a clinical-stage cannabinoid therapeutics company. The company's focus is the development of safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system - Permetrex for direct skin delivery of active pharmaceuticals in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1308 - Plaque Psoriasis, BTX1204 - Atopic Dermatitis, and BTX 1701 - Mild Acne. The majority of Revenue is Derived from Australia.
Featured Articles and Interviews
Mar 25, 2025
ASX Cannabis Stocks: 10 Biggest Companies in 2025
Jan 29, 2024
Top 3 ASX Cannabis Stocks
Apr 13, 2023
How to Invest in CBD Stocks on the ASX
Press Releases
See More Press Releases
Alert Options
No alert set
INN Article Notification
Alert Option
You will be notified when this event occurs. No additional settings needed.


